Danqing Kong
No. 188 Shizi Street
Suzhou, 215006, China
Suzhou, 215006, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.
Journal: Bone marrow transplantation
Published: April 26, 2026
Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in China.
Journal: Hematological oncology
Published: October 03, 2025
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma.
Journal: Cancer immunology, immunotherapy : CII
Published: June 01, 2025
Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis.
Journal: Frontiers in oncology
Published: September 04, 2024
Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Journal: Frontiers in immunology
Published: April 05, 2023
Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study.
Journal: Annals of hematology
Published: February 27, 2023
The coexistence of antiβ2 glycoprotein 1 antibody antibody has no effect on hemophilia A patient.
Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Published: August 18, 2022
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.
Journal: British journal of haematology
Published: July 08, 2022
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Journal: Frontiers in immunology
Published: June 15, 2022
Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy.
Journal: Hematological oncology
Published: December 23, 2021
Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.
Journal: Leukemia & lymphoma
Published: October 20, 2021
Last Updated: 09/26/2026